TrialBMC cancer2024

Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study.

Yu Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.